Dominant type-1 cytokine production is induced in a murine model of systemic histoplasmosis. We used this model to investigate whether the presence of antagonistic cytokines during T cell priming changes the polarity of T
Introduction
Upon antigen stimulation, naive CD4 + T lymphocytes are induced to differentiate into two distinct subsets (1) (2) (3) . The T h 1 subset produces IFN-c, IL-2 and lymphotoxin (4, 5) . The T h 2 subset produces IL-4, IL-5, IL-9, IL-10 and IL-13 (4, 5) . Similar to CD4 + Tcells, the CD8 + Tcells are also divided into two different subsets that secrete distinct patterns of cytokines (6, 7) . Type-1 cytokines promote macrophage activation and contribute to the pathogenesis of autoimmune disorders and the elimination of intracellular pathogens (1, 2), while type-2 cytokines contribute to the pathogenesis of allergic diseases and host protection against helminthic infections (1, 2) . Type-1 and type-2 cytokines are mutually antagonistic (8) . The biological importance of the mutual antagonism between type-1 and type-2 cytokines for humans was suggested by an epidemiological survey in Japanese children (9) . The study demonstrated an inverse association between tuberculin response and atopic disorder (9) . Subsequent to this observation, successful attempts were made in animals to reduce allergic response to ovalbumin peptide (OVA) by injecting live or killed intracellular organisms, shifting T h 2-dominant response to a T h 1-dominant one (10) (11) (12) . Conversely, when mice with established T h 2-dominant OVA-induced airway hypersensitivity response were infected with Listeria, the non-lethal infection became lethal (13) . Pre-established Schistosoma infection in mice also delays Leishmania lesion development (14) . Results of these studies show that exposure to agents that induce a type-1 response can reduce the allergic response to an allergen. Likewise, induction of a type-2 response interferes with host resistance to an intracellular pathogen. However, these studies did not clarify how these manipulations affect the generation of effector T cells or reveal the duration of cytokineassociated immune deviation.
Studies herein were designed to address these issues. Mice were treated with GaMd to induce the production of multiple cytokines, including small quantities of IL-2 and IFN-c and larger amounts of IL-4, IL-6, IL-9 and IL-10, creating a predominantly type-2 cytokine milieu (15) . Since Histoplasma capsulatum is an intracellular pathogen of the macrophage, macrophages stimulated by IFN-c are activated to inhibit the replication of the yeast (16) . The ability of animals to mount a type-1 cytokine response is vital to the clearance of this fungus (17, 18) . Employing GaMd to establish a predominantly type-2 cytokine environment prior to infection, we examined how type-2 cytokines regulate a host defense mechanism that is type-1 cytokine dependent.
Methods

Mice
C57BL/6 wild-type (WT), IL-4
ÿ/ÿ C57BL/6J-Il4 tm1Cgn (19) and IL-10 ÿ/ÿ C57BL/6-Il10 tm1Cgn mice (20) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) and bred in the Laboratory Animal Center of National Taiwan University College of Medicine. The animals were housed in sterilized cages fitted with filter cage tops and fed with sterilized food and water. IL-4 ÿ/ÿ
IL-10
ÿ/ÿ mice were generated by intercrossing F1 offspring of IL-4 ÿ/ÿ and IL-10 ÿ/ÿ parents. IL-4 and IL-10 gene deficiencies were confirmed by amplifying genomic tail DNA. The tail DNA obtained from 4-week-old mice was purified with a DNeasy TM tissue kit (Qiagen, Basel, Switzerland). Sequences for PCR primers were: Il-4, TGCATTGTTAGCATCTCTTGA (sense) and CCCTTCTCCTGTGACCTCGTT (antisense); Il-10, ATGCCTGGCTCAGCACTGCTA (sense) and TACAAAGAAA-GTCTTCACCTG (antisense). Confirmed IL-4 ÿ/ÿ IL-10 ÿ/ÿ mice were then intercrossed and their progeny were used in the experiments. All mice were bred and sera were tested for anti-mycoplasma and anti-mouse hepatitis virus antibodies. Serological results were all negative for these antibodies.
Fungus infection
Yeast cells of H. capsulatum strain 505 were cultured in brainheart infusion agar supplemented with cysteine (1 mg ml ÿ1 ) and glucose (20 mg ml ÿ1 ) at 37°C for 3 days. Yeast cells were prepared from fresh cultures. Mice were inoculated intravenously with 2.5 3 10
4 Histoplasma yeast cells.
Media and antibodies
RPMI 1640 (HyClone, Logan, UT, USA) was supplemented with 10% heat-inactivated FCS (HyClone), 1 mM sodium pyruvate (GIBCO-BRL, Grand Island, NY, USA), 2 mM Lglutamine, 0.1 mM non-essential amino acids, 100 U ml ÿ1 penicillin, 100 lg ml ÿ1 streptomycin, 25 mM HEPES buffer and 5 3 10 ÿ5 mM 2-mercaptoethanol (Sigma-Aldrich, St Louis, MO, USA). Purified anti-mouse CD16/32 mAb (clone 93), FITC-conjugated mAbs to CD4 (RM4-5), CD8 (53-6.7), CD3 (145.2C11) and CD25 (PC61.5), PE-conjugated mAbs to IFN-c (XMG1.2), IL-4 (11B11) and IL-10 (JES5-16E3) and allophycocyanin-conjugated mAbs to CD4 (GK1.5) were purchased from eBioscience (San Diego, CA, USA). PEconjugated rat IgG1 and rat IgG2b (eBioscience) were used as isotype controls.
Experimental design
To detect GaMd-induced cytokine production, mice were given two intraperitoneal injections of GaMd, 0.3 ml each, on days 0 and 6. Before the second injection, mice were bled and the sera were collected for the determination of IgE levels. Expression of IL-4, IL-10 and IFN-c mRNA in the spleen was determined by competitive reverse transcription (RT)-PCR. At day 12, GaMd-induced IL-4-, IL-10-and IFN-c-producing cells were analyzed by flow cytometry. Normal goat serum (Biological Industries, Israel) was used as control. To determine the effect of GaMd on Histoplasma infection, mice were given two intraperitoneal injections of GaMd on days ÿ6 and ÿ1 and infected intravenously with Histoplasma on day 0. At different time points after infection, spleens were harvested and homogenized for fungous counts and single-cell suspensions were prepared for immunostaining.
RT-PCR
Briefly, total RNA was extracted from spleens with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction. Five micrograms of total RNA was reverse-transcribed with Superscript TM II RNase H ÿ reverse transcriptase (Invitrogen) and oligo-dT primer. Serial 2-fold dilutions of a known concentration of competitor cDNA pMUS-3 (21) and an appropriate dilution of the sample cDNA were simultaneously amplified in the same PCR. The relative amount of the two PCR products is used to determine the concentration of input WT cDNA relative to the known concentration of the competitor. WTand pMUS-3 template DNA for a housekeeping gene, b 2 -microglobulin (b 2 -m), provided an internal control. Sequences of the primers used were: IL-4: sense primer, TCGGCATTTTGAACGAGGTC; antisense primer, GAAAAG-CCCGAAAGAGTCTC (PCR product 216 bp); IL-10: sense primer, ATGCAGGACTTTAAGGGTTACTTG; antisense primer, TAGACACCTTGGTCTTGGAGCTTA (PCR product 254 bp); IFN-c: sense primer, GCTCTGAGACAATGAACGCT; antisense primer, AAAGAGATAATCTGGCTCTGC (PCR product 227 bp); b 2 -m: sense primer, TGACCGGCTTGTATGCTATC; antisense primer, CAGTGTGAGCCAGGATATAG (PCR product 222 bp). Cycling conditions were: 94°C for 5 min, one cycle, and 94°C for 50 s, 60°C for 45 s, 72°C for 45 s, 40 cycles, followed by final extension at 72°C for 10 min. Cytokine mRNA was then normalized against b 2 -m mRNA. Fold increase of cytokine mRNA in GaMd-treated mice was determined against cytokine mRNA in control serum-treated mice.
To determine inducible nitric oxide synthase (iNOS) and arginase mRNA expression, peritoneal macrophages were harvested from Histoplasma-infected mice with GaMd or control serum treatment. Total RNA was extracted and reverse-transcribed as described above. cDNA was amplified in the presence of iNOS (22) ). After blocking, diluted serum samples (50 ll per well) from untreated or GaMd-treated mice were added. After overnight incubation at 4°C, biotinylated antimouse IgE detection antibody at 2 lg ml ÿ1 (BD PharMingen) was added. Streptavidin-alkaline phosphatase (BD PharMingen) was added to the wells and p-nitrophenyl phosphate (pNPP) substrate was added for color development. Light absorbance was read at 405 nm. The IgE concentrations in the serum samples were calculated from the standard curve established by using known concentrations of purified mouse IgE (BD PharMingen).
Fungous counts
Spleens and lungs were homogenized in RPMI 1640 medium, and 10-fold serially diluted. One hundred microliters of diluted homogenates were plated onto Sabouraud's agar plates containing 0.1% (w/v) bactopeptone, 0.2% (w/v) dextrose and 0.2% (w/v) agar. The plates were incubated at 30°C and the colony-forming units were enumerated 7-10 days later.
IFN-c ELISA
Spleen cells were collected from normal or infected mice that had been treated with GaMd or control goat serum, and singlecell suspensions were prepared. Heat-killed (60°C, 2 h) Histoplasma yeast cells were added to the spleen cell cultures (1 3 10 7 ml ÿ1 ) at a 1 : 40 yeast to spleen cell ratio. Culture supernatants were collected at 24 h of culture and stored at ÿ80°C. The IFN-c concentration in the culture supernatants was determined by an ELISA kit (eBioscience).
Intracytoplasmic cytokine staining for IL-4-, IL-10-and IFN-c-producing cells and flow cytometric analysis
To detect Histoplasma-specific cytokine-producing cells, spleen cells were collected from normal and infected mice with GaMd or control serum treatment and cultured in medium alone or in medium containing heat-killed Histoplasma yeast cells for 24 h. During the last 6 h of culture, 3 lM monensin (Sigma) was added. Cells were then harvested, blocked with purified anti-CD16/CD32 and stained with 1 lg ml ÿ1 FITCconjugated anti-CD4 or anti-CD8 and 1 lg ml To detect GaMd-induced intracytoplasmic IL-4-, IL-10-and IFN-c-producing cells, spleen cells were collected from mice 6 days after the second GaMd injection or at different time points after infection. Spleen cells were cultured in complete RPMI medium containing 0.4 ng ml ÿ1 recombinant human IL-2 for 24 h without antigenic stimulants. Monensin was added during the last 6 h of culture. Intracytoplasmic staining was performed as described above. To determine the percentage of IL-10-producing cells, spleen cells were harvested from GaMdtreated or -untreated mice, and stained with FITC-conjugated anti-F4/80, or allophycocyanin-conjugated anti-CD4 and FITCconjugated anti-CD25, and PE-conjugated anti-IL-10 mAbs.
Statistical analysis
Student's t-test was used for statistical analysis. P values <0.01 were considered significant. All data were expressed as mean 6 standard deviation.
Results
Histoplasma infection induces a dominant type-1 response
Mice were given an intravenous inoculation of Histoplasma yeast cells. Flow cytometric analysis showed that Histoplasmaspecific IFN-c-producing cells developed in the spleen at as early as day 3 of infection ( Fig. 1A) . The peak of IFN-c response was at day 14 and remained high until day 21 (Fig. 1A) . On the contrary, only low numbers of Histoplasma-specific IL-4-producing cells were detectable during the course of infection (Fig. 1A) . Therefore, infection by Histoplasma induced a dominant type-1 cytokine response. In addition, IFN-c-deficient mice, in contrast to WT mice, were unable to reduce the fungal load (Fig. 1B) , confirming the importance of IFN-c. IL-4 or IL-10 deficiency, on the other hand, did not affect the clearance of the fungus (Fig. 1C ). These data show that a polarized type-1 response is induced in mice infected with Histoplasma. By using this model, we investigated whether the presence of antagonistic cytokines would change the polarity of T cells.
GaMd treatment induces a dominant type-2 cytokine response
It has been reported that immunization with GaMd induces the expression of multiple cytokines with type-2 dominance (15). To study the effects of antagonistic cytokines on type-1 cytokine response to Histoplasma infection, we used GaMd to create a strong type-2 cytokine milieu in mice. Since GaMdinduced cytokine expression is transient (15) , and clearance of Histoplasma takes a few weeks (24), we sought to prolong the expression of T h 2 cytokines in mice by injecting mice a second time with GaMd, 6 days after the initial injection. http://intimm.oxfordjournals.org/ only 2.7-fold ( Fig. 2A and B) . These results are consistent with published data showing IL-4 and IL-10 mRNAs increased as early as day 3 after GaMd treatment with peaks at days 5 and 6 (15) . Consistent with the IL-4 response, serum IgE levels were high (13.36 6 2.04 lg ml ÿ1 ) in immunized mice as compared with untreated controls (0.11 6 0.02 lg ml ÿ1 ). Flow cytometric analysis of intracytoplasmic cytokine staining revealed that 6 days after the second GaMd injection, spleen cells in cultures containing IL-2, without further stimulation, constitutively produced IL-4, IL-10 and IFN-c (Fig. 2C) . These results confirmed that GaMd treatment created a dominant type-2 cytokine environment in the spleen. By using GaMd, we then studied how these cytokines affect the differentiation of IFN-cproducing T cells in response to Histoplasma infection.
GaMd treatment profoundly suppresses Histoplasmainduced IFN-c response
Mice were infected with Histoplasma 1 day after the second GaMd injection when the antagonistic cytokine levels were high. Intracytoplasmic cytokine staining demonstrated that GaMd treatment significantly reduced the number of both CD4 + and CD8 + IFN-c-producing cells (Fig. 3A) as well as CD4 ÿ
CD8
ÿ IFN-c-producing cells in Histoplasma-infected mice. The total number of IFN-c-producing cells in mice receiving control serum was (18.4 6 6.9) 3 10 5 and that in GaMd-treated mice was (5.9 6 2.9) 3 10 5 , of which CD4 ÿ CD8 ÿ IFN-c-producing cells constituted one-tenth of the former and one-twentieth of the latter (data not shown). ELISA measurement of splenocyte IFN-c secretion supported the intracytoplasmic staining results (Fig. 3B) . In addition, analysis of the mean fluorescence intensity of intracellular IFN-c staining, an indicator of IFN-c production at the single-cell level, demonstrated that GaMd treatment decreased the quantity of IFN-c produced by individual, Histoplasma-stimulated IFN-cproducing T cells (WT in Fig. 5B and C). These results demonstrate that GaMd treatment prior to infection creates a cytokine environment that inhibits the generation of Histoplasmaspecific IFN-c-producing T cells and their production of IFN-c. Since Histoplasma infection requires a type-1 response for clearance, we then examined how the presence of antagonistic cytokines affects fungal clearance.
GaMd treatment retards fungal clearance
The fungal burdens in GaMd-treated mice were compared with those in the control mice at different time points. Figure 4 (A) and Table 1 show that fungal burdens in the spleens of mice given GaMd treatment were significantly higher than in the control mice from the first time point on. The fungal burdens in control mice peaked at day 7 of infection and then decreased by a factor >10 by day 14, showing that these mice acquired the ability to clear the fungus after day 7. In contrast, fungal burdens in GaMd-treated mice rose from day 3 through day 14, demonstrating that the mice were unable to control the infection. Moreover, GaMd treatment not only increased fungal burdens in the spleen but also that in the lungs (Fig. 4B and Table 1 ). Thus, reduction of IFN-c-producing cells by GaMd treatment results in retarded fungal clearance.
IL-4 is partially responsible for GaMd-induced suppression
We then employed mice with cytokine gene defects to identify the cytokines that suppress the generation of IFN-c-producing cells. While the number of Histoplasma-specific IFN-cproducing T cells was not much different between Histoplasmainfected WT and IL-4 ÿ/ÿ mice that had received control goat serum (P = 0.04, Fig. 5A ), the number of Histoplasma-specific IFN-c-producing Tcells was significantly higher in GaMd-treated IL-4 ÿ/ÿ mice than in GaMd-treated WT mice (P < 0.001 for CD4 + T cells and P = 0.01 for CD8 + T cells, Fig. 5A ). Thus, IL-4 contributes to GaMd-induced inhibition of the generation of IFNc-producing T cells in Histoplasma-infected mice. However, additional factor(s) must be involved in GaMd inhibition of the Histoplasma ( Fig. 5B and C) . The suppressive effect of GaMd on the generation of IFNc-producing cells as well as that on the quantity of IFNc produced by individual cells were partially reversed in IL-4 ÿ/ÿ mice ( Fig. 5A-C) . Results of ELISA measurement of IFN-c secreted also supported this conclusion as IFN-c production by Histoplasma-infected IL-4 ÿ/ÿ mice treated with GaMd was 11.9 6 7.9 ng ml ÿ1 and that by those without GaMd treatment was 30.6 6 11.5 ng ml ÿ1 (Fig. 5D ).
IL-4 and IL-10 together mediate GaMd-induced suppression of IFN-c response
Because IL-10 can inhibit CD4 + T cell cytokine production and proliferation (25) and IL-10 expression is induced by GaMd (Fig. 2) , we then determined whether IL-10 was the additional factor that mediates GaMd-induced suppression of IFN-c production. As shown in Fig. 2 , GaMd induced IL-10 production. The source of IL-10 was mainly F4/80 + macrophages, while CD4 + CD25 + T cells also contributed to IL-10 production (Fig. 6) . We then generated mice defective in both the IL-4 and IL-10 genes and compared the numbers of Histoplasmaspecific IFN-c-producing T cells in IL-4 ÿ/ÿ
IL-10
ÿ/ÿ mice with that in WT, IL-4 and IL-10 single-gene knockout mice (Fig. 7A) . While GaMd-induced reduction of IFN-c-producing T cell number was partially reversed by selective deficiency of IL-4 
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http://intimm.oxfordjournals.org/ or IL-10, it was totally absent in IL-4 ÿ/ÿ IL-10 ÿ/ÿ mice. Moreover, the effect of IL-4 and IL-10 on GaMd-induced inhibition was also observed in CD4 ÿ
CD8
ÿ IFN-c-producing cells (Fig. 7A ). In addition, deficiency of both IL-4 and IL-10 completely reversed GaMd-induced suppression of the quantity of IFN-c made by individual IFN-c-producing CD8 + T cells and partially reversed the suppression of the quantity of IFN-c made by individual IFNc-producing CD4 + T cells in Histoplasma-infected mice ( Fig. 7B  and C) . ELISA measurement demonstrated that IFN-c secretion by Histoplasma-infected IL-4 ÿ/ÿ IL-10 ÿ/ÿ mice treated with GaMd was 43.6 6 3.2 ng ml ÿ1 , while that by those without treatment was 43.2 6 19.6 ng ml ÿ1 (Fig. 7D) . Thus, both IL-4 and IL-10 mediate the suppressive effect of GaMd on the generation of IFN-c-producing cells. However, although depletion of IL-4 and IL-10 reconstituted the IFN-c response, it only partially restored fungal clearance in the spleen and the lungs (Table 1) .
To evaluate whether the lower number of IFN-c-producing T cells in the spleens of GaMd-treated, Histoplasma-infected mice was the result of poor Tcell recruitment, we compared the numbers of splenic CD4 + and CD8 + T cells in uninfected and Histoplasma-infected mice that had been treated with GaMd or control goat serum. There was no difference in the total numbers of CD4 + and CD8 + Tcells in infected WTand cytokine gene-deficient mice with or without GaMd treatment (data not shown). Thus, GaMd suppression of the generation of IFN-cproducing Tcells in Histoplasma-infected mice is not a result of poor T cell recruitment.
The presence of IL-4 and IL-10 during T cell priming does not change the ultimate polarity of type-1 T cells
Since cytokines present at the stage of TCR ligation are considered most critical in affecting the differentiation of naive T cells to become type-1 or type-2 T cells (2, 3), we investigated whether the presence of IL-4 and IL-10 during T cell priming for Histoplasma-specific response would change the polarity of T cells. We followed the temporal relationship between GaMd induction of IL-4-and IL-10-producing cells and Histoplasma induction of IFN-c-producing cells. An inverse relationship between type-1 and type-2 T cell populations was observed (Fig. 8A) . Although GaMd-induced IFN-c was present in early phase of infection (between days 3 and 5), the numbers of Histoplasma-specific IFN-c-producing T cells rose after GaMd-induced IL-4 and IL-10 waned (Fig. 8A) . By day 21, the numbers of IFN-c-producing CD4 + and CD8 + T cells in GaMd-treated, Histoplasma-infected mice were (7.0 6 1. ÿ1 in control serum-treated group and 0.35-1.73 ng ml ÿ1 in GaMdtreated group. Ten to 17 mice were included in each group. The experiment was repeated three times (**P < 0.001, ***P < 0.0001 comparing GaMd-treated mice with those treated with control serum). burden was reduced to a level close to that of control serumtreated mice (Fig. 8B ). These results demonstrate that the presence of IL-4 and IL-10 during T cell priming suppresses the generation but does not change the ultimate polarity of type-1 T cells. (26) . La Flamme et al. co-infected mice with Schistosoma and Leishmania and found that the resolution of Leishmania cutaneous lesions and parasitemia was delayed. Concurrent with delayed resolution was production of IL-4 and reduced amounts of IFN-c, tumor necrosis factor (TNF)-a and nitric oxide (14) .
Discussion
By pre-treating mice with GaMd, we have shown that the presence of IL-4 and IL-10 during T cell priming suppresses the generation of IFN-c-producing cells in Histoplasmainfected mice. This suppression affected both the number of IFN-c-producing cells and the level of IFN-c made by each IFN-c-producing cell and retarded fungal clearance. However, as the effect of GaMd wore off, the numbers of IL-4-and IL-10-producing cells declined, the number of IFN-c-producing cells rose and the fungus was cleared. By ruling out the possibility of poor T cell recruitment, our data suggest that the presence of IL-4 and IL-10 delays T cell priming toward type-1 T cells but does not ultimately suppress the generation of polarized type-1 T cells.
GaMd treatment induces production of predominant type-2 cytokines (15). IL-4-producing cells were identified to be mostly CD4 T cells and basophils (27, 28) . In this study, we identified the major source of GaMd-induced IL-10 to be the Normal goat serum was used as control. b Numbers in parenthesis represent the number of mice used. *P < 0.01, **P < 0.001, ***P < 0.0001 comparing GaMd treatment with control serum treatment. Fig. 4 . GaMd treatment retards fungal clearance. After two intraperitoneal injections of GaMd, mice were infected by Histoplasma. Fungous counts in the spleens (A) and lungs (B) were enumerated at days 3, 5, 7 and 14 after infection. Four to 10 mice from three independent experiments were included in each group (#P < 0.05,*P < 0.01, ***P < 0.0001 comparing GaMd-treated mice with those treated with control serum).
macrophages, while CD4 + CD25 + , the putative regulatory T cells (29) , constituted only a fraction of IL-10 + cells (Fig. 6A  and B) . Therefore, GaMd-induced suppressive effect on type-1 cell development is mainly through the macrophages. Regardless of the source of IL-4 and IL-10, the suppressive effect of GaMd is reversed in IL-4 ÿ/ÿ IL-10 ÿ/ÿ mice. The clearance of Histoplasma is IFN-c (Fig. 1B) as well as TNF-a dependent (30) . While the source of IFN-c is mainly CD4 + T cells and CD8 + T cells (Fig. 7A ), TNF-a is produced by the macrophages (30) but not T cells (data not shown). Both IFN-c and TNF-a are crucial to macrophage iNOS expression and fungal clearance (31, 32) . Interestingly, GaMd treatment increases the expression of arginase mRNA (arginase/HPRT increased from 0.383 to 0.677) and reduces that of iNOS mRNA (iNOS/HPRT decreased from 0.297 to 0.134) in mice before infection. The suppressive effect of GaMd on iNOS mRNA expression remains until day 7 after infection (iNOS/ HPRT = 0.365 in GaMd-treated versus 0.726 in untreated). By that time, the effect of GaMd on arginase mRNA expression no longer exists (iNOS/HPRT = 0.643 in GaMd-treated versus 0.765 in untreated). It appears that in the presence of IL-4 and IL-10, macrophage activation by alternative and/or deactivation pathway(s) occurs (33) . When the effect of GaMd wanes, the alternative pathway of macrophage activation also subsides. Concurrent with delayed T cell priming toward type-1 cells in GaMd-treated mice, iNOS mRNA up-regulation is also delayed after Histoplasma infection. As a consequence, fungal clearance is retarded.
Although the cytokines present at the stage of TCR ligation are most critical in affecting the differentiation of naive Tcells to become type-1 or type-2 T cells, the nature of the invading pathogen, the route and dose of the antigen given and the genetic background of the host are all important factors that affect T cell differentiation (2, 3) . In our study, it appears that the presence of IL-4 and IL-10 during T cell priming in response to infection by Histoplasma suppressed the initial generation of IFN-c-producing cells but did not change the ultimate polarity of Histoplasma-specific T cells. Alternatively, the presence of IL-4 and IL-10 in early phase of infection delayed but did not affect the induction of IFN-c-producing cells. Interestingly, GaMd administered during the course of infection did not change type-1 response or the outcome of infection (data not shown). Mocci and Coffman reported that polarized Leishmania-specific T h 1 population was changed to T h 2 by in vitro culture with a high concentration of IL-4 (34). While change of T cell polarity was possible in vitro, our results showed that the nature of the invading pathogen dictates the ultimate polarity of the responding T cells even when antagonistic cytokines are present.
Pathogens differ from soluble antigens in that the pathogens continue to replicate until effector T cells are induced and activated. As the pathogen replicates, the antigen dose increases. Although it is not clear what mechanism underlies the effects of antigen dose on T cell subset development, the possibility exists that high dose of Histoplasma antigen continues to stimulate IL-12 production by antigen-presenting cells. When antagonistic cytokines wane, the development of IFN-c-producing cells rapidly resumes.
The understanding of the effect of cytokines on T cell differentiation is mostly at the level of CD4 + T cells. In response ÿ/ÿ mice treated with either GaMd or control serum. Spleen cells were harvested from mice at day 7 after infection. Culture supernatant was collected at 24 h and the IFN-c production was determined by ELISA. Eight to nine mice were included in each group (*P < 0.01 comparing GaMd-treated mice with those treated with control serum). to Histoplasma infection, not only CD4 + but also CD8 + T cells were activated to produce IFN-c (Fig. 4) . It has been shown in Tbet knockout mice that IFN-c transcription is impaired in CD4 + T and NK cells but not in CD8 + T cells (35) . It is eomesodermin, a member of the T-box gene family, that plays a major role in regulation of CD8 T cell IFN-c production (36) . These data indicate that the regulation of IFN-c gene transcription in CD4 + and CD8 + T cells is controlled by distinct transcriptional 
IL-10
ÿ/ÿ mice treated with GaMd or control serum. Three mice from three independent experiments were included in each group. mechanisms. Results in Fig. 7(B and C) (Table 1 ). It is possible that clearance is not dependent on IFN-c production alone. Other factors like TNF-a have been shown to be important (38, 39) . Another possible explanation is that lots of low IFN-c-producing cells may not produce enough IFN-c to ensure rapid clearance (Fig. 7) .
A major conclusion of the present study is that IL-4 and IL-10 can be powerfully suppressive of the generation of antigenspecific IFN-c-producing cells in vivo. The type-2 cytokines present where and when T cells are primed delay the development but do not change the ultimate polarity of type-1 cells. One implication of these findings is that hosts that mount a dominant type-2 cytokine response as a result of helminth infection or exposure to an allergen may make inadequate type-1 cytokine responses to control infectious agents that require a type-1 cytokine response. However, should the type-2 immune response wane, the type-1 cytokine-dependent host defense mechanism can be restored.
